Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France.
Groupe de Recherche Clinique CARMAS, Université Paris-Est-Créteil (UPEC), Créteil, France.
Nat Commun. 2022 Oct 12;13(1):6025. doi: 10.1038/s41467-022-33801-z.
Infection with SARS-CoV-2 variant Omicron is considered to be less severe than infection with variant Delta, with rarer occurrence of severe disease requiring intensive care. Little information is available on comorbid factors, clinical conditions and specific viral mutational patterns associated with the severity of variant Omicron infection. In this multicenter prospective cohort study, patients consecutively admitted for severe COVID-19 in 20 intensive care units in France between December 7th 2021 and May 1st 2022 were included. Among 259 patients, we show that the clinical phenotype of patients infected with variant Omicron (n = 148) is different from that in those infected with variant Delta (n = 111). We observe no significant relationship between Delta and Omicron variant lineages/sublineages and 28-day mortality (adjusted odds ratio [95% confidence interval] = 0.68 [0.35-1.32]; p = 0.253). Among Omicron-infected patients, 43.2% are immunocompromised, most of whom have received two doses of vaccine or more (85.9%) but display a poor humoral response to vaccination. The mortality rate of immunocompromised patients infected with variant Omicron is significantly higher than that of non-immunocompromised patients (46.9% vs 26.2%; p = 0.009). In patients infected with variant Omicron, there is no association between specific sublineages (BA.1/BA.1.1 (n = 109) and BA.2 (n = 21)) or any viral genome polymorphisms/mutational profile and 28-day mortality.
感染 SARS-CoV-2 变异株奥密克戎被认为比感染变异株德尔塔的病情较轻,需要重症监护的严重疾病发生率较低。关于与奥密克戎变异株感染严重程度相关的合并症因素、临床情况和特定病毒突变模式的信息较少。在这项多中心前瞻性队列研究中,我们纳入了 2021 年 12 月 7 日至 2022 年 5 月 1 日期间法国 20 个重症监护病房连续收治的因 COVID-19 而严重的患者。在 259 名患者中,我们表明感染奥密克戎变异株(n=148)的患者的临床表型与感染德尔塔变异株(n=111)的患者不同。我们没有观察到德尔塔和奥密克戎变异株谱系/亚谱系与 28 天死亡率之间存在显著关系(调整后的比值比[95%置信区间]为 0.68[0.35-1.32];p=0.253)。在感染奥密克戎的患者中,43.2%免疫功能低下,其中大多数患者接受了两剂或更多剂疫苗(85.9%),但对疫苗接种的体液反应较差。感染奥密克戎变异株的免疫功能低下患者的死亡率明显高于非免疫功能低下患者(46.9%比 26.2%;p=0.009)。在感染奥密克戎变异株的患者中,特定亚谱系(BA.1/BA.1.1(n=109)和 BA.2(n=21))之间或任何病毒基因组多态性/突变特征与 28 天死亡率之间均无关联。